Nadia Harbeck
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
Papers in
- Cancer Research 365
- Breast Cancer Treatment Studies 296
- Cancer Genomics and Diagnostics 44
- Protease and Inhibitor Mechanisms 42
- Oncology 433
- HER2/EGFR in Cancer Research 191
- Cancer Treatment and Pharmacology 119
- Cancer Cells and Metastasis 36
- Co-authors
- Michael Gnant (16 shared papers)Manfred Schmitt (89 shared papers)Christoph Thomssen (79 shared papers)Fátima Cardoso (28 shared papers)Javier Cortés (38 shared papers)Seock‐Ah Im (17 shared papers)Dennis J. Slamon (12 shared papers)Cynthia Huang Bartlett (12 shared papers)
- Journals
- Annals of Oncology (126 papers)Breast Care (94 papers)Journal of Clinical Oncology (39 papers)European Journal of Cancer (31 papers)Breast Cancer Research and Treatment (30 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Nadia Harbeck
832 papers receiving 62.3k citations
Nadia Harbeck's Hit Papers
Peers
Comparison fields: 5 of 181
- Cancer Research 19.4k
- Oncology 29.3k
- Pulmonary and Respiratory Medicine 18.6k
- Genetics 3.1k
- Radiology, Nuclear Medicine and Imaging 4.5k
Countries citing papers authored by Nadia Harbeck
This map shows the geographic impact of Nadia Harbeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Harbeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Harbeck more than expected).
Fields of papers citing papers by Nadia Harbeck
This network shows the impact of papers produced by Nadia Harbeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Harbeck. The network helps show where Nadia Harbeck may publish in the future.
Co-authors
The 25 scholars most cited alongside Nadia Harbeck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 878 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Palbociclib and Letrozole in Advanced Breast Cancer Hit paper breakdown → | 2016 | 2258 |
| 2 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2258 |
| 3 | Breast cancer Hit paper breakdown → | 2019 | 2256 |
| 4 | Breast cancer Hit paper breakdown → | 2016 | 1898 |
| 5 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1875 |
| 6 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Hit paper breakdown → | 2016 | 1806 |
| 7 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2016 | 1457 |
| 8 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1374 |
| 9 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1299 |
| 10 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Hit paper breakdown → | 2007 | 1251 |
| 11 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Hit paper breakdown → | 2020 | 1014 |
| 12 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 993 |
| 13 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 948 |
| 14 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 915 |
| 15 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Hit paper breakdown → | 2018 | 870 |
| 16 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2020 | 854 |
| 17 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Hit paper breakdown → | 2018 | 784 |
| 18 | Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hit paper breakdown → | 2010 | 776 |
| 19 | Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer Hit paper breakdown → | 2019 | 746 |
| 20 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Hit paper breakdown → | 2020 | 721 |
About Nadia Harbeck
Nadia Harbeck is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 878 papers that have together received 63.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (296 papers), Advanced Breast Cancer Therapies (209 papers), HER2/EGFR in Cancer Research (191 papers), Cancer Treatment and Pharmacology (119 papers), Cancer Genomics and Diagnostics (44 papers), Protease and Inhibitor Mechanisms (42 papers), Cancer Cells and Metastasis (36 papers) and Breast Lesions and Carcinomas (35 papers). The work is most often cited by research in Cancer Research (19.4k citations), Oncology (29.3k citations), Pulmonary and Respiratory Medicine (18.6k citations), Genetics (3.1k citations) and Radiology, Nuclear Medicine and Imaging (4.5k citations). Nadia Harbeck has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Michael Gnant, Manfred Schmitt, Christoph Thomssen, Fátima Cardoso, Javier Cortés, Seock‐Ah Im, Dennis J. Slamon, Cynthia Huang Bartlett, Hiroji Iwata and Nicholas C. Turner. Their work appears in journals such as Annals of Oncology, Breast Care, Journal of Clinical Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.